vtyx

Ventyx Biosciences (VTYX) presents an interesting profile, particularly when examining the interplay of institutional sentiment and market short interest.

Here's a look at some key data points from Fintel:

• Institutional Ownership: VTYX currently has 231 institutional owners, holding a significant 48.93 million shares. However, recent filings indicate a notable shift, with institutional shares held decreasing by 21.10% quarter-over-quarter, and the number of institutional owners declining by 5.35% over the same period. This suggests a degree of institutional de-risking or reallocation, despite prominent firms like BlackRock and Point72 remaining among the largest shareholders.1
• Short Interest: The stock shows a considerable short interest, with 4.97 million shares currently shorted. The Short Interest % Float stands at 8.94%, and the Days to Cover is 9.60, indicating it would take nearly ten trading days for short sellers to cover their positions based on average daily volume. Furthermore, the Off-Exchange Short Volume Ratio was 42.89% as of August 6, 2025, suggesting a substantial portion of shorting activity occurs away from traditional exchanges.2
• Analyst Outlook & Fundamentals: While the company is a clinical-stage biopharmaceutical firm focused on inflammatory diseases, it is currently unprofitable, reporting an EPS (TTM) of -1.74.3 Despite this, analysts maintain an average one-year price target of $12.24, with a median of $12.75 as of August 6, 2025, projecting significant revenue growth from $295 million in 2026 to over $2.2 billion by 2030.4 The Piotroski F-Score, a measure of financial health, is low at 2.00 out of 9.3

The combination of decreasing institutional ownership and high short interest, alongside ambitious future revenue projections for an currently unprofitable company, highlights a divergence in market sentiment that warrants close monitoring. Investors might find value in further exploring the specific institutional filings to understand the nature of recent sales and the catalysts driving the bullish analyst forecasts.

did they close the lly deal ?